Piramal Critical Care
Find. Read. Learn
News & Events
Learn more about upcoming events, new press releases, and the latest news from Piramal Critical Care.
Learn more about upcoming events, new press releases, and the latest news from Piramal Critical Care.
Peter DeYoung is the CEO of Piramal Global Pharma and a member of the Piramal Pharma Operating Board. Piramal Global Pharma is comprised of Piramal Pharma Solutions and Piramal Critical Care business units. In his current role, Peter is responsible for steering strategy and driving profitable growth of these businesses.
Prior to this, he has spearheaded several leadership mandates at the Piramal Group, including CEO, Piramal Critical Care and President, Life Sciences.
Previously, Mr. DeYoung worked in various investing and consulting roles in healthcare in the USA, Europe and India. He joined McKinsey & Company in New York after graduating from Princeton, where he worked on a number of projects for pharmaceutical and medical device companies. He was then seconded by McKinsey to the World Economic Forum in Geneva, Switzerland as part of the Global Health Initiative. Mr. DeYoung returned to McKinsey in New York and later in Mumbai, where he focused on the pharmaceutical and healthcare practice. Later, he joined the Blackstone Group’s Private Equity Division in Mumbai where he was part of the deal team for several significant transactions, across a wide spectrum of industry sectors in India.
Mr. DeYoung holds a Master’s Degree in Business Administration from Stanford University (Arjay Miller Scholar), California, USA and a Bachelor’s of Science Degree in Engineering from Princeton University, New Jersey, USA (summa cum laude).
Michael Logerfo is the President & COO of Piramal Critical Care. Michael is responsible for sales, marketing, regulatory, R&D, manufacturing, and supply chain.
Prior to joining Piramal, Michael was with Sagent Pharmaceuticals for more than 9 years, where he worked with an entrepreneurial team to develop and execute an innovative outsourced-supply business model that enabled Sagent to establish a product portfolio and pipeline that drove sales to over $300M. Michael was involved in every aspect of the company’s growth from start-up through IPO and a NASDAQ listing, and most recently served as Sagent’s President. From 1999 to 2006, Michael served as CEO of Flavine International, a commercial and regulatory agent and marketing partner, primarily for API manufacturers.
Michael earned a Bachelor of Arts in Government and a Juris Doctor from Georgetown University prior to beginning his career as an attorney in private practice in New York and New Jersey. Michael and his family have been residents of Somerset County, New Jersey for more than 25 years.
Michael Teague is the Executive Vice President of Global Operations at Piramal Critical Care. He is responsible for overseeing production planning & inventory control, order fulfillment, procurement, sourcing and vendor management, logistics, distribution and warehouse management, and vaporizer operations, including the management of the key vaporizer vendor relationships.
Michael began his career with Pfizer Inc. in the Groton Manufacturing Plant. Over the next 20 years, he was promoted through a series of positions overseeing pharmaceutical and chemical manufacturing and operations. After Pfizer, Michael consulted for many notable Fortune 500 firms such as Novartis, Pfizer, Fujisawa Pharmaceutical, Danisco, and Pepsi. During his time as a business development and pharmaceutical consultant, he traveled extensively where he was involved in due-diligence for acquisitions, joint-venture negotiations, competitive intelligence assessments, and technical transfers to Asia. In 2008, he headed a Bethlehem, Pennsylvania anesthetic manufacturing site, which was plagued with high costs, compliance and safety issues and an inability to meet demand prior to the Piramal acquisition in 2009, and turned it around. Today the site stands as a flagship site in the Piramal portfolio of operations. In 2012, Michael was promoted to Vice President of Supply Chain and charged with establishing and leading an integrated global supply chain for Piramal Critical Care.
Michael graduated from Worcester Polytechnic Institute with a Bachelor of Science in Chemical Engineering and currently resides in Lehigh Valley, Pennsylvania with his wife and two children.
Rashida Najmi is Chief Quality Officer at Piramal Critical Care. She is responsible for establishing and implementing related quality standards, handling inspections, and maintaining regulatory track records of various regulatory agencies such as FDA, MHRA, and PMD.
Rashida maintains more than 26 years of experience in quality management of NDA, INDA, CRO, API- intermediates, API (drug substance), various dosage formulations (drug product), product development, clinical, pharmacovigilance, and biologic, with renowned companies like Shreya Life Sciences and ACG. During Rashida’s ongoing tenure at Piramal, she has successfully maintained the compliance benchmark higher than the regulatory requirement at all Pharma Solutions manufacturing sites across geographies. She is also instrumental in establishing ‘Quality’ as a differentiator for business growth and harmonizing “best in class” quality practices across Piramal.
Rashida is a Pharmacist and a postgraduate in Human Resources and is a Qualified Lead Auditor in ISO 9000 and ISO 14000 (from QMI, UK), certified in HACCP (from UN/ FAO), 5’S’ (from JMA), and OHSAS. In 2015, World Quality Congress awarded Rashida with the title of “50 Most Influential Quality Professionals.” She has been a jury member in several academic and quality awards and also an active member of industry forums like ISPE, IDMA, PDA, and OPPI.
Richard Leone is the Vice President of Regulatory Affairs for Piramal Critical Care. He is responsible for the development and execution of regulatory strategies and submissions with Health Authorities globally.
Prior to joining Piramal, Richard has worked at several pharmaceutical companies including Teva Pharmaceuticals, Bausch & Lomb, Ranbaxy Pharmaceuticals, Phibro Animal Health and Shire US. In his more than 15 years in the pharmaceutical industry, Richard has held positions in Quality Assurance, Quality Control and Regulatory Affairs. His regulatory experience includes APIs and a plethora of dosage forms including sterile products, solid orals, semi-solids, liquids, transdermal, respiratory and nasal products, sublingual and buccal films, and medicated animal feeds.
Richard earned his Bachelor of Science in Toxicology and Master of Science in Regulatory Affairs and Quality Assurance from St. John’s University. He is also RAC (US) certified.
Richard and his family reside in Bucks County, Pennsylvania.
Steven Braun is the Vice President of Sales and Marketing in the Americas for Piramal Critical Care. He is responsible for leading the sales and marketing teams in North and South America for both the human and animal health businesses.
Steven started his career as a Registered Nurse in Kansas City, Missouri. After five years of working in a cardio-thoracic ICU, Steven moved into the field of Personal Financial Planning with IDS/American Express. After three years with IDS/American Express, Steven joined Abbott Laboratories assuming roles in sales, sales training, contract marketing, sales management, and executive sales. With the spin-off of Hospira Worldwide, Inc. from Abbott Laboratories in 2004, Steven moved into the role of marketing manager for generic injectable drugs. He then moved to assume the role of Vice President, National Accounts for Hospira until joining Piramal in September of 2013.
In addition to his nursing degree, Steven holds a Bachelor of Arts in Management and Human Relations from Mid-America Nazarene University in Olathe, Kansas.
Billy Hargan is the Vice President of Sales, RoW for Piramal Critical Care. He is responsible for leading the commercial teams for the European, Asian, Middle East, and Australian markets.
Billy started his career in the pharmaceutical industry in a sales role before progressing through product and international product management. He spent four years as Country Manager for Boots in Pakistan before leading the BASF Pharma international marketing team, where he was responsible for the worldwide introduction of Reductil. Following the acquisition by Abbott, Billy moved to lead the UK Hospital Division, which held a market-leading position in anesthesia. When it was spun out of Abbott, Billy joined Hospira and led the formation of the EMEA commercial team, including the recruitment of Country Managers for the European affiliates and the establishment and management of key distributor partnerships.
Billy has a BSc in Physiology from the University of Glasgow and lives in Surrey, England with his wife and two adult sons.
Vikram Duggal heads the Human Resources function. Vikram has rich 22+ years of professional experience in the field of designing and implementing Organization Transformation interventions, Talent sourcing, Talent management & Employee Relations in Pharma manufacturing and Financial services.
In his previous role, Vikram worked with Sun Pharmaceuticals, where he has played a variety of roles including Head HR for Emerging Markets business spanning over 40+ countries. He has previously worked with Ranbaxy, PineBridge Investments (erstwhile AIG Investments), ICICI Prudential Life Insurance and Hindustan Unilever Limited.
Vikram has done his Masters in HR from XLRI, Jamshedpur and a Bachelor’s degree in Science with a specialization in Statistics.
Ahmad Aboelezz is Head, Legal, Global Pharma. He is responsible for leading the legal function for Piramal’s Global Pharma businesses, including M&A and Business Development transactions, litigation and dispute resolution management as well as aligning corporate legal strategy to align with Piramal’s continued growth and mission.
Ahmad has over 20 years of experience as a life sciences legal professional and business executive in increasing and diverse roles of responsibility, including 12 years at Ranbaxy Pharmaceuticals, where he last held a dual role as Vice President, Business Development and Vice President & General Counsel, North America and served as part of a management team that achieved $1 billion in
sales. He has advised pharmaceutical companies through some of their biggest achievements and their toughest challenges, including serving as principal lead for numerous high-level transactions, litigations and investigations before federal and state agencies. Ahmad oversaw and managed successful legal victories and settlement agreements, including in connection with Sensipar®,
Lipitor®, Nexium®, Diovan® and Aricept®. Prior to going in-house, Ahmad was in private practice in New Jersey focusing on general corporate matters, governance, licensing and M&A transactions.
Ahmad earned a Bachelor of Science in Finance from Rutgers University and a Juris Doctor degree from Rutgers School of Law. He currently resides with his wife and three children in Franklin Park, New Jersey.